Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Fig. 3

a: Growth curves for all eight PDO lines treated with cibisatamab or controls during 10 days of co-culture. Each PDO was cultured with T cells from three different allogeneic donors at an E:T ratio of 2:1 and means are shown. b: Comparison of the fraction of CEAhi cells in each PDO with the growth reduction in achieved at the essay endpoint in panel A. c: Correlation analysis of growth reduction and the fraction of CEAhi cells for all PDOs. A linear regression line and the Pearson correlation coefficient and p value of the significance test are shown

Back to article page